Dupixent and Narrowband UVB for Atopic Dermatitis

Psoriasis Treatment Center of Central New Jersey

Status and phase: Enrolling; Phase 4

Conditions: Atopic Dermatitis

Treatments: Drug: Dupixent

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05285839

ETC01

Details and patient eligibility

About

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Full description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female adult ≥ 18 years of age;

• Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

  • EASI score of 16 or greater,
  • IGA score of 3 or greater
  • BSA of 10% or greater,

Exclusion criteria

• Subjects with previous exposure to dupilumab.
• Known or suspected hypersensitivity to dupilumab or any of its excipients.
• History of photosensitivity.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Dupixent and Narrowband UVB

Experimental group

Description:

Dupixent and Narrowband UVB

Treatment:

Drug: Dupixent